JM
Therapeutic Areas
Comanche Biopharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CBP-4888 | sFlt1-mediated Preterm Preeclampsia | Clinical Development (Phase not specified) |
Leadership Team at Comanche Biopharma
SJ
Scott Johnson, M.D.
Chief Executive Officer & Co-Founder
RC
Richard Colvin, MD, PhD
Global Head of R&D